180 Life Sciences Stock (NASDAQ:ATNF)
Previous Close
$2.35
52W Range
$1.16 - $17.75
50D Avg
$2.67
200D Avg
$2.40
Market Cap
$4.63M
Avg Vol (3M)
$2.02M
Beta
0.25
Div Yield
-
ATNF Company Profile
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
ATNF Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. |
| CNSP | CNS Pharmaceuticals, Inc. |
| PHIO | Phio Pharmaceuticals Corp. |
| EFTR | eFFECTOR Therapeutics, Inc. |
| IMMX | Immix Biopharma, Inc. |
| CYTO | Altamira Therapeutics Ltd. |
| SONN | Sonnet BioTherapeutics Holdings, Inc. |
| ZURA | Zura Bio Limited |
| ENVB | Enveric Biosciences, Inc. |
| CDIO | Cardio Diagnostics Holdings, Inc. |
| PALI | Palisade Bio, Inc. |